Publication of Cancellation of Entries for Kinds of Medical Devices from the Australian Register of Therapeutic Goods – Lorraine Howell - 146122

Overview

The Therapeutic Goods Act 1989, enacted in 1989, governs the regulation of therapeutic goods in Australia, including medical devices, to ensure they are safe and of high quality. The Act was introduced to address the need for a comprehensive framework to regulate the manufacturing, supply, advertising, and importation of therapeutic goods, thus protecting public health by preventing the distribution of unsafe or ineffective products. This legislative measure was enacted by the Australian Parliament with the policy objective of safeguarding the health and safety of the public by ensuring that therapeutic goods meet appropriate standards. The notice of cancellation of an entry for a kind of medical device from the Australian Register of Therapeutic Goods is a specific instance of the enforcement of the Act, demonstrating its application in maintaining the integrity and safety of the therapeutic goods market in Australia. In this instance, the cancellation was due to incorrect certifications concerning the classification of the medical device, highlighting the importance of accurate information in the registration process.

Scope and Application

The Therapeutic Goods Act 1989 applies to medical devices, including their registration, classification, and standards, within Australia. Section 41GP specifically addresses the publication of the cancellation of entries for kinds of medical devices from the Australian Register of Therapeutic Goods. This act applies to entities such as sponsors and manufacturers who are responsible for ensuring the correct classification of medical devices before they are listed in the Register. The geographic reach of this legislation is national, applying across all states and territories of Australia. Notably, this particular notification pertains to the cancellation of an entry for an elastic bandage manufactured by Xanamed (South Africa) and sponsored by Lorraine Howell. The cancellation was due to incorrect certifications related to the classification of the medical device. The Act does not detail specific exclusions or thresholds but relies on subordinate instruments to extend or restrict its application. This legislative framework ensures that only correctly classified and certified medical devices are available in the Australian market, thereby protecting public health and safety.

Key Provisions

The main sections of this legislation focus on the cancellation of certain entries in the Australian Register of Therapeutic Goods (ARTG). Specifically, section 41GP of the Therapeutic Goods Act 1989 (the Act) deals with the publication of the cancellation of entries for kinds of medical devices from the ARTG (subsection 41GN(1)(f)). In this instance, the cancellation pertains to an entry for a specific kind of medical device, namely an elastic bandage, identified by the ARTG number 146122. The sponsor of this entry is Lorraine Howell, and the manufacturer is Xanamed, based in South Africa. Under the Act, the obligations and requirements imposed on the parties involved include ensuring that the certifications provided in the application to list a medical device in the ARTG are accurate and align with the correct classification of the device. In this case, the certification for the elastic bandage was found to be incorrect concerning the classification of the device, leading to its cancellation. The delegate of the Secretary to the Department of Health and Ageing, Irina Tsyganova, has the authority to publish such cancellations to inform relevant parties of the changes in the ARTG. Failure to comply with the requirements set out by the Act can lead to various consequences. While the specific legislative section does not detail offences or penalties for incorrect certifications, breaches of the Act can result in administrative actions, including the cancellation of ARTG entries, as demonstrated in this instance. Additionally, more severe breaches may lead to further civil or criminal consequences, including fines and imprisonment, depending on the nature and severity of the breach. The maximum penalties can vary, but they are outlined in other sections of the Therapeutic Goods Act 1989. It is essential for manufacturers and sponsors to ensure that all certifications and applications are accurate to avoid such outcomes.